JNJ-67484703, a Novel PD-1 Agonist Antibody, Demonstrates Favorable Safety, Target Engagement, and Preliminary Clinical Benefit in Phase Ib Trial for Active Rheumatoid Arthritis

Rheumatoid Arthritis (RA) The immunopathological mechanism andPD-1Closely related to abnormal channel function,In synovial tissuePD-1High-expression PathogenicityTCell infiltration is the key to disease progression.Different from those commonly used in cancer treatmentPD-1Antagonist,PD-1Agonists activate byPD-1Inhibiting Pathways and Restoring Immune Homeostasis Provides New Insights for the Treatment of Autoimmune Diseases.

Recently,Johnson & JohnsonPublishedⅠbClinical research in the period confirmed that the newPD-1Agonist AntibodyJNJ-67484703In activityRAThe safety profile was good in patients, with clear signals of biological activity and clinical benefit, laying an important foundation for subsequent development.

One: Drug Design with Dual Mechanism Targeting PathogenicityTCell

    JNJ-67484703Is a humanizedIgG1Antibodies, whose mechanism of action differs from traditional onesPD-1Targeted drugs, with unique advantages:AndPD-1Combine Without InterferencePD-L1/PD-L2AndPD-1Interaction, avoiding impact on physiological immune regulation。At the same time, it hasDual Mode of Action: On the one hand, asPD-1Agonist InhibitionTCell receptor signaling, on the other hand, through antibody-dependent cellular cytotoxicity (ADCC) Effect DepletionPD-1+TCell。

Prioritizing action onPD-1High expression (PD-1^high) PathogenicityTCells (such as follicular helperTCells, Peripheral AssistanceTCells), these cells areRAThe core driving factors of synovial inflammation and antibody production.

Two: Randomized double-blind placebo-controlledⅠbPhase Trial

Study PopulationInclude44Example ActivityRAPatients, all meet2010YearACR/EULARClassification criteria, for at least1Traditional synthetic disease-modifying antirheumatic drugs (csDMARDs) had an inadequate response and continued to receive a stable dose of methotrexate treatment. Patients were randomly assigned toJNJ-67484703 2mg/kgGroup (n=5）、3mg/kgGroup (n=25`) or placebo group (`n=14）。

Method of AdministrationForSubcutaneous injection, on the0、1、2、4、6、8、10Weekly Medication Administration7Times, followed up to the24Week。Primary EndpointForAdverse events occurred during the treatment (TEAEs) Incidence rate, evaluation of safety and tolerability。Secondary EndpointForThe12Based on the weekCC-reactive protein28Joint Disease Activity Score (DAS28-CRP) Change from baseline,ACRResponse Rate (ACR20/50/70), and3mg/kgGroup CyclePD-1+TChanges in cell count.

 Three: Safety and ActivityObtainedDual Verification

Incidence of Adverse Events Balanced:JNJ-67484703 2mg/kgGroup,3mg/kgGroup and placebo groupTEAEsThe incidence rates were respectively80.0%、68.0%And71.4%, with no difference in severity, and no deaths reported.。Infection-related in Two Drug Treatment GroupsTEAEsThe incidence rates are all20.0%, compared with the placebo group (21.4%) Close, no unexpected infection risks occurred。The drug delivery system demonstrated high safety, with no immune-related serious adverse events observed, only2Example: The patient was severelyTEAE(Secondary pneumonia from pneumonia, COVID-19 infection) Discontinue medication.

    JNJ-67484703Can significantly reduce circulation inPD-1^highCD4+TCell Proportion,The12Zhou Shi2mg/kgGroup and3mg/kgThe baseline ratio of the group decreased to0.12And0.33, andPD-1Low expression (PD-1^low）TThe decrease in cell count was relatively small.PD-1Negative (PD-1neg）TNo persistent decline in cells。CorrectPD-1Highly Expressed Follicular HelperTCells, Peripheral AssistanceTThe effect of cell depletion was the most significant,IndicateAction DependencyPD-1Expression Density。Consistent with the targeting of drug design.

In terms of efficacy,The12At the same time,JNJ-67484703 3mg/kgGroupDAS28-CRPLeast Squares Mean Decrease from Baseline1.96, compared with the placebo group (decreased1.27) The difference is-0.69, although it did not reach statistical significance, it showed a clear trend of clinical benefit.。Multiple Indicators Improved，3mg/kgGroup Clinical Disease Activity Index (CDAI) The decline was greater (-23.83vsPlacebo Group-14.96），SoftJoint Count, Swollen Joint Count,CRPHorizontal, etc.ACRAll component indicators showed numerical improvement.。At the same time3mg/kgGroup28.0%of patients reachedDAS28-CRPLow Disease Activity (≤3.2), higher than the placebo group (14.3%）。

 Summary and Reflection

    JNJ-67484703As the first one inRAConducting clinical research in ChinaPD-1Agonist,Targeting Pathogenicity Through a Unique Dual MechanismPD-1+TCell, inⅠbShowed good safety, clear biological activity, and potential clinical benefits in the trial period.The study isRATreatment Opens New Pathways, BreakingPD-1The traditional understanding that targeted drugs are only used for cancer treatment.

HoweverThe sample size is small (especially2mg/kgGroup Only5Example), limited follow-up time, and the clinical endpoint did not reach statistical significance; larger-scale trials are needed to verify efficacy.。Currently, the clinical progress of this project has temporarily stalled, possibly due to the lack of significant efficacy.。

    Safety,tolerability, and efficacy of the PD-1 agonist antibody JNJ-67484703 in adults with active rheumatoid arthritis: results of a multicenter, double-blind, placebo-controlled, randomized, multiple-dose phase Ib study. Ther Adv Musculoskelet Dis . 2025 Oct 21:17:1759720X251385857. doi: 10.1177/1759720X251385857. eCollection 2025.